Business Insider24 天
AIM ImmunoTech announces data pubished on Part 1 study on Ampligen
AIM ImmunoTech (AIM) announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen as a component of a chemokine ...